These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24012151)

  • 1. Censoring on outcome is not valid in self-controlled case series studies.
    Farrington P
    J Clin Epidemiol; 2013 Dec; 66(12):1428-9. PubMed ID: 24012151
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations of within-person study designs. In reply.
    Nicholas JM; Grieve AP; Gulliford MC
    J Clin Epidemiol; 2013 Dec; 66(12):1429. PubMed ID: 24012152
    [No Abstract]   [Full Text] [Related]  

  • 3. Within-person vs. traditional study designs: how to evaluate study designs?
    Chen H; Nembhard WN; Stockwell HG
    J Clin Epidemiol; 2013 Mar; 66(3):350-1. PubMed ID: 22959590
    [No Abstract]   [Full Text] [Related]  

  • 4. Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs.
    Nicholas JM; Grieve AP; Gulliford MC
    J Clin Epidemiol; 2012 Apr; 65(4):384-93. PubMed ID: 22197519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone and pioglitazone. Beware fractures.
    Dixit A; Pandey P
    BMJ; 2009 Sep; 339():b3957. PubMed ID: 19808816
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetes drug pioglitazone (Actos): risk of fracture.
    Meymeh RH; Wooltorton E
    CMAJ; 2007 Sep; 177(7):723-4. PubMed ID: 17823139
    [No Abstract]   [Full Text] [Related]  

  • 7. Fracture risk is a class effect of glitazones.
    Short R
    BMJ; 2007 Mar; 334(7593):551. PubMed ID: 17363794
    [No Abstract]   [Full Text] [Related]  

  • 8. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considering competing risks . . . Not all black and white.
    Cauley JA; Ensrud KE
    Arch Intern Med; 2008 Apr; 168(8):793-5. PubMed ID: 18443252
    [No Abstract]   [Full Text] [Related]  

  • 10. Study confirms link between certain diabetes drugs and fractures.
    Harv Womens Health Watch; 2010 May; 17(9):6. PubMed ID: 20593558
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone and the thiazolidinediones: a changing context.
    Kenny C
    Prim Care Diabetes; 2007 Dec; 1(4):185-6. PubMed ID: 18632043
    [No Abstract]   [Full Text] [Related]  

  • 13. Thiazolidinedione use and the risk of fractures.
    Reblin T
    CMAJ; 2009 Apr; 180(8):841. PubMed ID: 19364797
    [No Abstract]   [Full Text] [Related]  

  • 14. Thiazolidinediones in heart failure: slippery when wet.
    Khush KK
    J Card Fail; 2008 Aug; 14(6):453-5. PubMed ID: 18672191
    [No Abstract]   [Full Text] [Related]  

  • 15. Type 2 diabetes, thiazolidinediones: bad to the bone?
    Watts NB; D'Alessio DA
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122
    [No Abstract]   [Full Text] [Related]  

  • 16. Skeletal toxicity of thiazolidinediones.
    Grey AB
    Ann Intern Med; 2008 Apr; 148(7):563. PubMed ID: 18378956
    [No Abstract]   [Full Text] [Related]  

  • 17. Thiazolidinediones and fluid retention.
    Kiryluk K; Isom R
    Kidney Int; 2007 Sep; 72(6):762-8. PubMed ID: 17637710
    [No Abstract]   [Full Text] [Related]  

  • 18. The rise and fall of rosiglitazone.
    Nissen SE
    Eur Heart J; 2010 Apr; 31(7):773-6. PubMed ID: 20154334
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient.
    Sisson EM; Mills J; Chin L
    Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries CS; Russell-Jones DL
    BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.